BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 11828947)

  • 1. A study of the combination of gemcitabine hydrochloride (LY188011) and cisplatin in non-small-cell lung cancer: 3-week schedule.
    Kunikane H; Kurita Y; Watanabe K; Yokoyama A; Noda K; Fujita Y; Yoneda S; Nakai Y; Niitani H
    Int J Clin Oncol; 2001 Dec; 6(6):284-90. PubMed ID: 11828947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gemcitabine versus the combination of cisplatin and etoposide in patients with inoperable non-small-cell lung cancer in a phase II randomized study.
    Perng RP; Chen YM; Ming-Liu J; Tsai CM; Lin WC; Yang KY; Whang-Peng J
    J Clin Oncol; 1997 May; 15(5):2097-102. PubMed ID: 9164223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of altering administration sequence of docetaxel, gemcitabine and cisplatin in patients with advanced non-small cell lung cancer.
    Harita S; Watanabe Y; Kiura K; Tabata M; Takigawa N; Kuyama S; Kozuki T; Kamei H; Tada A; Okimoto N; Genba K; Tada S; Ueoka H; Hiraki S; Tanimoto M
    Anticancer Res; 2006; 26(2B):1637-41. PubMed ID: 16619585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cisplatin, gemcitabine and vinorelbine in locally advanced or metastatic non-small-cell lung cancer: a phase I study.
    Frasci G; Panza N; Comella P; Nicolella GP; Natale M; Pacilio C; Gravina A; Caputi V; Botti G; Comella G
    Ann Oncol; 1997 Oct; 8(10):1045-8. PubMed ID: 9402180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Docetaxel/gemcitabine or cisplatin/gemcitabine followed by docetaxel in the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC): results of a multicentre randomized phase II trial.
    Binder D; Schweisfurth H; Grah C; Schäper C; Temmesfeld-Wollbrück B; Siebert G; Suttorp N; Beinert T
    Cancer Chemother Pharmacol; 2007 Jun; 60(1):143-50. PubMed ID: 17031643
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A triplet chemotherapy with cisplatin, docetaxel and gemcitabine in patients with advanced non-small-cell lung cancer: a phase I/II study.
    Tabata M; Kozuki T; Ueoka H; Kiura K; Harita S; Tada A; Shibayama T; Takigawa N; Yonei T; Gemba K; Segawa Y; Kishino D; Tada S; Hiraki S; Tanimoto M;
    Cancer Chemother Pharmacol; 2007 Jun; 60(1):53-9. PubMed ID: 17009034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cisplatin, gemcitabine, and vinorelbine combination therapy in advanced non-small-cell lung cancer: a phase II randomized study of the Southern Italy Cooperative Oncology Group.
    Comella P; Frasci G; Panza N; Manzione L; Lorusso V; Di Rienzo G; Cioffi R; De Cataldis G; Maiorino L; Bilancia D; Nicolella G; Natale M; Carpagnano F; Pacilio C; De Lena M; Bianco A; Comella G
    J Clin Oncol; 1999 May; 17(5):1526-34. PubMed ID: 10334540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biweekly cisplatin and gemcitabine with two different doses in non small cell lung cancer patients: A retrospective singlecenter experience.
    Dogan E; Ucar M; Sakalar T; Derin S; Bozkurt O; Inanc M; Ozkan M
    J BUON; 2018; 23(4):1070-1076. PubMed ID: 30358213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new cisplatin/gemcitabine schedule in locally advanced (IIIB) and metastatic (IV) non-small cell lung cancer: relationship between dose-intensity and efficacy. A phase II study.
    Rossi D; Graziano F; Catalano V; Giordani P; Fedeli SL; Alessandroni P; Fedeli A; Dennetta D; Ugolini M; Catalano G
    Anticancer Res; 2002; 22(5):3087-92. PubMed ID: 12530048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Weekly gemcitabine and monthly cisplatin for advanced non-small cell lung carcinoma.
    Abratt RP; Hacking DJ; Goedhals L; Bezwoda WR
    Semin Oncol; 1997 Jun; 24(3 Suppl 8):S8-18-S8-23. PubMed ID: 9207311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of low-dose cisplatin and gemcitabine for treatment of elderly patients with advanced non-small-cell lung cancer.
    Feliu J; Martín G; Madroñal C; Rodríguez-Jaráiz A; Castro J; Rodríguez A; Checa T; Bolaño M; Casado E; González-Barón M
    Cancer Chemother Pharmacol; 2003 Sep; 52(3):247-52. PubMed ID: 12783203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II study of a novel gemcitabine plus cisplatin regimen administered every three weeks for advanced non-small-cell lung cancer.
    Castellano D; Lianes P; Paz-Ares L; Hidalgo M; Guerra JA; Gómez-Martín C; Gómez H; Calzas J; Cortés-Funes H
    Ann Oncol; 1998 Apr; 9(4):457-9. PubMed ID: 9636840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gemcitabine (GEM) and carboplatin (CBDCA) versus cisplatin (CDDP) and vinblastine (VLB) in advanced non-small-cell lung cancer (NSCLC) stages III and IV: a phase III randomised trial.
    Grigorescu AC; Draghici IN; Nitipir C; Gutulescu N; Corlan E
    Lung Cancer; 2002 Jul; 37(1):9-14. PubMed ID: 12057861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gemcitabine, vinorelbine and cisplatin combination chemotherapy in advanced non-small cell lung cancer: a phase II trial.
    Laack E; Mende T; Dürk H; Kneba M; Dickgreber N; Welte T; Müller T; Scholtze J; Graeven U; Jasiewicz Y; Edler L; Hossfeld DK
    Eur J Cancer; 2002 Mar; 38(5):654-60. PubMed ID: 11916547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Three-week versus four-week schedule of cisplatin and gemcitabine: results of a randomized phase II study.
    Soto Parra H; Cavina R; Latteri F; Sala A; Dambrosio M; Antonelli G; Morenghi E; Alloisio M; Ravasi G; Santoro A
    Ann Oncol; 2002 Jul; 13(7):1080-6. PubMed ID: 12176787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined cisplatin and gemcitabine for non-small cell lung cancer: influence of scheduling on toxicity and drug delivery.
    Abratt RP; Sandler A; Crinò L; Steward WP; Shepherd FA; Green MR; Nguyen B; Peters GJ
    Semin Oncol; 1998 Aug; 25(4 Suppl 9):35-43. PubMed ID: 9728583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paclitaxel, cisplatin, and gemcitabine combination chemotherapy within a multidisciplinary therapeutic approach in metastatic nonsmall cell lung carcinoma.
    Rodriguez J; Cortes J; Calvo E; Azinovic I; Fernandez-Hildago O; Martinez-Monge R; Garzon C; de Irala J; Martinez-Aguillo M; Ramon Y Cajal T; Brugarolas A
    Cancer; 2000 Dec; 89(12):2622-9. PubMed ID: 11135224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II, open-label trial of bortezomib (VELCADE(®)) in combination with gemcitabine and cisplatin in patients with locally advanced or metastatic non-small cell lung cancer.
    Kontopodis E; Kotsakis A; Kentepozidis N; Syrigos K; Ziras N; Moutsos M; Filippa G; Mala A; Vamvakas L; Mavroudis D; Georgoulias V; Agelaki S
    Cancer Chemother Pharmacol; 2016 May; 77(5):949-56. PubMed ID: 26994909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I study of escalating doses of oxaliplatin in combination with fixed dose gemcitabine in patients with non-small cell lung cancer.
    Bidoli P; Stani SC; Mariani L; De Candis D; Cortinovis D; Aglione S; Zilembo N; Toffolatti L; Formisano B; Bajetta E
    Lung Cancer; 2004 Feb; 43(2):203-8. PubMed ID: 14739041
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial assessing the combination of gemcitabine and cisplatin in advanced non-small cell lung cancer (NSCLC).
    Antón A; Díaz-Fernández N; González Larriba JL; Vadell C; Masutti B; Montalar J; Barneto I; Artal A; Rosell R
    Lung Cancer; 1998 Nov; 22(2):139-48. PubMed ID: 10022221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.